Cell Rep: New research confirms that Redsewey can indeed be an effective treatment for COVID-19!

July 19, 2020 // In a recent study published in the international journal Cell Reports, scientists from Vanderbilt University Medical Center and others found that Redsewe may indeed be able to potentially suppress SARS-CoV-2 infection, while improving lung function in mice infected with the SARS-CoV-2 virusPhoto Credit: National Institute of Allergy and Journal, NIH These preclinical findings may help explain the clinical effects of Redsiwe in the treatment of PATIENTs with COVID-19, who have been treated for patients admitted to hospital with COVID-19 on the basis of sympathetic use since late January and FebruaryIn April, preliminary findings from an adaptive COVID-19 therapy trial at several institutions, including Vanderbilt University Medical Center, showed that patients treated with Redsewe recovered more quicklyResearcher Dr Andrea Pruijssers said all of the research based on Redsewe was encouraging, but further research was needed, and it was important to prove directly its resistance to SARS-CoV-2 in laboratories and animal disease models; In this study, the researchers were the first to demonstrate for the first time that Redsewe was effective in inhibiting the activity of SARS-CoV-2 in continuous and progenitor human lung cell cultures, and for the first time they found that Redsewe can block the progression of the virus in mouse models; COVID-19 has infected more than 12 million people worldwide and caused about 600,000 deaths, and is at least the third serious human case of disease caused by the bat-transmitted coronavirus since 2003; In addition to SARS-CoV-2, the researchers also found that Redsewe is effective against multiple coronavirus infections, including those that may be carried in other bats in the future; Original origins: Andrea JPruijsers, Amelia SGeorge, Alexandra Sch?fer, et alRemdesivir Inhibits SARS-CoV-2 in lung human cells and chimeric SARS-CoV-CoV-2 RNA polymerase inDOI: 10.1016/j.celrep.2020.107940.